Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Vasculitis
•
Hospital Medicine
How would you approach EGPA with renal involvement that was on maintenance Rituximab, last infusion two months ago and develops new onset liver involvement?
Other causes if liver disease excluded.
Related Questions
What would be your approach to managing severe ANCA-associated vasculitis in a patient who is also septic from a bacterial infection?
Would you pursue a kidney biopsy in a patient with stable stage 1 AKI, bland urine sediment, and a positive MPO titer without systemic signs of vasculitis?
How would you approach a male in his 60s with bilateral optic perineuritis/neuritis on MRI, steroid-responsive bilateral jaw pain, normal ESR/CRP, negative temporal artery biopsy, and elevated IgG4?
Excluding CLL, in which patients would you screen for hypogammaglobulinemia?
How do you approach tapering of tocilizumab used for a history of GCA with vision loss?
What biologic or conventional/synthetic DMARD would you use as a steroid sparing agent in a patient with GCA and a history of diverticulitis?
How would you approach the workup of a female patient who has recurrent sinusitis with polyps (biopsy showed active and chronic inflammation) and myocarditis, but negative ANCA and normal eosinophil counts?
Would you consider anti-IL-5 therapy (mepolizumab or benralizumab) to either prevent or treat the more severe manifestations of eosinophilic granulomatosis with polyangiitis, such as "infiltrative" (e.g., cardiomyopathy, pulmonary infiltrates, or gastroenteritis) or "vasculitic" (e.g., neuropathy, palpable purpura, or glomerulonephritis)?
What treatment regimen would you recommend for a patient with biopsy-proven giant cell arteritis and diffuse cutaneous systemic sclerosis?
What options are available for patients who require high dose steroids while taking strong CYP4A4 inducers?